The University of Chicago Header Logo

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following properties of Dignam, James J.
overview Dr. Dignam's primary research involves the design, conduct, and analysis of cancer clinical trials, including early development (phase I), pilot efficacy and safety (phase II), and definitive evaluation (phase III) trials. He is the Executive Director of the Statistics and Data Management Center for NRG Oncology, a National Cancer Institute sponsored multi-center clinical trials group with over 500 recruitment sites in North America and beyond and over 100 active clinical trials. Dr. Dignam's methodology interests include trial monitoring and early stopping rules, competing risks, hazard function estimation, and prognostic modeling. He also has engaged in and led investigations into sociodemographic factors such as race/ethnicity and BMI/obesity on cancer prognosis and treatment response. Courses taught include introductory biostatistics, clinical trials, survival analysis, and regression modeling methods.
One or more keywords matched the following items that are connected to Dignam, James J.
Item TypeName
Concept Prognosis
Academic Article Prognosis among African-American women and white women with lymph node negative breast carcinoma: findings from two randomized clinical trials of the National Surgical Adjuvant Breast and Bowel Project (NSABP).
Academic Article Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes.
Academic Article Differences in breast cancer prognosis among African-American and Caucasian women.
Academic Article Is patient travel distance associated with survival on phase II clinical trials in oncology?
Academic Article Statistical considerations in assessing molecular markers for cancer prognosis and treatment efficacy.
Academic Article Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer.
Academic Article Effects of obesity and race on prognosis in lymph node-negative, estrogen receptor-negative breast cancer.
Academic Article The ongoing search for the sources of the breast cancer survival disparity.
Academic Article Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS.
Academic Article p53 as a marker of prognosis in African-American women with breast cancer.
Academic Article Conditional survival and the choice of conditioning set for patients with colon cancer: an analysis of NSABP trials C-03 through C-07.
Academic Article Diffusing capacity predicts long-term survival after lung resection for cancer.
Academic Article Optimization of response classification criteria for patients with malignant pleural mesothelioma.
Academic Article Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer.
Academic Article Prognosis after rectal cancer in blacks and whites participating in adjuvant therapy randomized trials.
Academic Article Obesity and breast cancer prognosis: an expanding body of evidence.
Academic Article Race and the prognostic influence of p53 in women with breast cancer.
Academic Article Patterns of missing mini mental status exam (MMSE) in radiation therapy oncology group (RTOG) brain cancer trials.
Academic Article Disease volumes as a marker for patient response in malignant pleural mesothelioma.
Academic Article A nomogram for individualized estimation of survival among patients with brain metastasis.
Academic Article Lung volume measurements as a surrogate marker for patient response in malignant pleural mesothelioma.
Academic Article Bayesian approach for flexible modeling of semicompeting risks data.
Academic Article Individualized dynamic prediction of prostate cancer recurrence with and without the initiation of a second treatment: Development and validation.
Academic Article A tissue biomarker-based model that identifies patients with a high risk of distant metastasis and differential survival by length of androgen deprivation therapy in RTOG protocol 92-02.
Search Criteria
  • Prognosis